Pharmacological interventions for somatoform disorders in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 11, 2014, Pages

  Kleinstäuber, Maria ^a   Witthöft, Michael ^b   Steffanowski, Andrés ^c   van Marwijk, Harm ^d   Hiller, Wolfgang ^b   Lambert, Michael J ^e  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF MANNHEIM   (Germany)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUPENTIXOL; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; NATURAL PRODUCT; NEUROLEPTIC AGENT; OPIPRAMOL; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ALLERGY; ANOREXIA; ARTHRITIS; ASTHENIA; BACKACHE; BLURRED VISION; BRONCHITIS; CLINICAL DECISION MAKING; CONSTIPATION; CONTUSION; CYSTITIS; DIARRHEA; DISEASE SEVERITY; DISTRESS SYNDROME; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ELEVATED BLOOD PRESSURE; FATIGUE; FLATULENCE; GASTRITIS; GASTROENTERITIS; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERSOMNIA; HYPERTENSION; HYPESTHESIA; INSOMNIA; LETHARGY; LOSS OF APPETITE; MICTURITION DISORDER; MIGRAINE; NAUSEA; NEURALGIA; NIGHTMARE; NOSE OBSTRUCTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOGENIC PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMATOFORM DISORDER; SOMNOLENCE; STAPHYLOCOCCAL SKIN INFECTION; STOMACH IRRITATION; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VERTIGO; VOMITING; XEROSTOMIA; META ANALYSIS; MIDDLE AGED; SOMATOFORM DISORDERS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS;

EID: 84922262168     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010628.pub2     Document Type: Review

References (220)

1. Altamura AC, Mauri MC, Regazzetti G, Coppola MT. L-sulpiride in the treatment of somatoform disturbances: a double-blind study with racemic sulpiride [L-sulpiride nel trattamento dei disturbi somatoformi: uno studio in doppio cieco vs sulpiride racema]. Minerva Psichiatrica 1991;32(1):25-9.
2. Aragona M, Bancheri L, Perinelli D, Tarsitani L. Randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. European Journal of Pain 2005;9(1):33-8.
3. Eberhard G, Vonknorring L, Nilsson HL, Sundequist U, Bjorling G, Linder H, et al.A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes. Neuropsychobiology 1988;19(1):25-34.
4. Han C, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, et al.Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial. Clinical Drug Investigation 2008;28(4):251-61.
5. Han C, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, et al.Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008;32(2):437-44.
6. Huang M, Luo B, Hu J, Wei N, Chen L, Wang S, et al.Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. International Clinical Psychopharmacology 2012;27(3):151-8.
7. Jiang X, Yang K, Hu W, Zheng JG. A clinical effective analysis of venlafaxine in treatment of somatoform disorders. Chinese General Practice 2005;8(14):1177-8.
8. Ju G. A study of venlafaxine in the treatment of somatization disorder. Medical Journal of Chinese People's Health 2003;15(10):590-4.
9. Kong LS, Li J, Zhang X. Comparison study of domestic paroxetine and amitriptyline in treatment of somatoform disorders randomized double-blind study. Medical Journal of Chinese People's Health 2004;10(12):733-4, 742.
10. Kroenke K, Benattia I, Musgnung J, Graepel J, Stahl S. Short-term treatment of depressed and anxious primary care patients with multiple, unexplained somatic symptoms: a pilot study. Neuropsychopharmacology 2004;29(Suppl 1):S210.
11. Kroenke K, Messina N, Benattia I, Graepel J, Musgnung J. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. Journal of Clinical Psychiatry 2006;67(1):72-80.
12. Li G, Jin W. Comparison study of paroxetine and paroxetine combined with quetiapine in treatment of somatoform disorder. Chinese Journal of Behavioral Medical Science 2006;15(7):598-9.
13. Luo YL, Zhang MY, Wu WY, Li CB, Lu Z, Li QW. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009;33(8):1522-5.
14. Kraft K. Additional benefit of Petasites hybridus (butterbur) in a four-combination for somatoform disorders. Focus on Alternative and Complementary Therapies 2010;15(1):25-6.
15. Melzer J. Results of a randomized, placebo-controlled pharmaco-clinical study with a combined herbal preparation for the treatment of patients with somatoform disorders [Ergebnisse einer randomisierten, placebokontrollierten pharmakoklinischen Studie mit einem pflanzlichen Kombinationspreparat zur Behandlung von Patienten mit somatoformen Störungen]. Schweizerische Zeitschrift für Ganzheitsmedizin 2012;24(5):284-6.
16. Melzer J, Schrade E, Brattström A, Schellenberg R, Saller R. Herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatization disorders: randomized, placebo-controlled pharmaco-clinical trial [Pflanzliches Kombinationspräparat mit und ohne Pestwurz (Ze 185) für die Behandlung von Patienten mit Somatisierungsstörungen: Eine randomisiert, placebokontrollierte pharmako-klinische Studie]. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Neurologie (DGPPN) Congress; 2009 Nov 25-28; Berlin, Germany. 2009.
17. Melzer J, Schrader E, Brattström A, Schellenberg R, Saller R. Fixed herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmaco-clinical trial. Phytotherapy Research 2009;23(9):1303-8.
18. Müller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosomatic Medicine 2004;66(4):538-47.
19. Müller JE, Wentzel I, Koen L, Niehaus DJ, Seedat S, Stein DJ. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. International Clinical Psychopharmacology 2008;23(1):43-8.
20. Ouyang H, Liu Y. Comparison of mirtazapine and amitriptyline in the treatment of somatoform disorders. Chinese Journal of Health Psychology 2006;14(5):560-1.
21. Pilowsky I, Barrow CG. A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable 'psychogenic' pain. Pain 1990;40(1):3-19.
22. Sanada K, Mimura M, Noda Y, Hida M, Nakahara M, Tsukurimichi A, et al.Comparison of effect of paroxetine and milnacipran for outpatients with pain disorder conference abstract. European Neuropsychopharmacology 2010;20 Suppl 3:S543.
23. Möller HJ, Volz HP, Stoll KD. Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression. Acta Neuropsychiatrica 2003;15(4):217-26.
24. Volz HP, Möller HJ, Reimann I, Stoll KD. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. European Neuropsychopharmacology 2000;10(3):211-7.
25. Anonymus. St. John's wort effective for somatoform disorders independent of depressive symptoms. Brown University Psychopharmacology Update 2003;14(2):3.
26. Murck H, Moller HJ, Volz HP. St. John's wort extract (LI 160) in somatoform disorders - results of a placebo-controlled trial. European Neuropsychopharmacology 2002;12(Suppl 3):S342.
27. Volz HP, Murck H, Kasper S, Moller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Erratum [Johanniskrautextrakt (LI 160) bei somatoformen Stoerungen: Ergebnisse einer plazebokontrollierten Studie. Erratum]. Psychopharmacology 2003;167(3):333.
28. Volz HP, Murck H, Kasper S, Möller HJ. St John's wort extract (li 160) in somatoform disorders: results of a placebo-controlled trial [Johanniskrautextrakt (LI 160) bei somatoformen Stoerungen: Ergebnisse einer plazebokontrollierten Studie]. Psychopharmacology 2002;164(3):294-300.
29. Wang YX, Ren ZH, Wang SJ. A double-blind study on trazodone in the treatment of persistent somatoform pain disorder. Chinese Journal of Pain Medicine 2003;9(2):70-2.
30. Xu J, Li S. Venlafaxine in the treatment of 35 cases of persistent somatoform pain disorder. Herald of Medicine 2004;23(1):397-99.
31. Yang Z, Lu X, Liu J, Zhang WB. A control study of venlafaxine in the treatment of somatoform disorder. Journal of Clinical Psychosomatic Diseases 2006;12(4):262-3.
32. Ye M, Xie Z, Wang J, Zheng W, Jiang D. Mirtazapine in treatment of somatization disorder. Clinical Medicine 2006;16(6):14-5.
33. Zhao H. A controlled study of mirtazapine and amitriptyline in somatization. Evaluation and Analysis of Drug-Use in Hospitals of China 2006;6(3):175-6.
34. Zitman FG, Linssen ACG, Edelbroek PM, van Kempen GMJ. Does addition of low-dose flupenthixol enhance the analgesic effects of low-dose amitriptyline in somatoform pain disorder?. Pain 1991;47(1):25-30.
35. Altamura AC, Di RA, Ermentini A, Guaraldi GP, Invernizzi G, Rudas N, et al.Levosulpiride in somatoform disorders: a double-blind, placebo-controlled cross-over study. International Journal of Psychiatry in Clinical Practice 2003;7(3):155-9.
36. Ballbe R, Jocano H. Action of WY 3498 in hysteria and anxiety neuroses [Acción del WY 3498 en neurosis histéricas o ansiosas.]. Prensa medica argentina 1970;58(19):946-50.
37. Bratfos O, Lingjaerde O, Salvesen C. Symptomatic relief of neurotic symptoms with tybamate: a double-blind, placebo-controlled study. Acta Psychiatrica Scandinavica 1967;43(3):282-5.
38. Cui GM, Wang XF, Liu JX. A controlled study of the treatment of electric acupuncture and low dose perphenazine on hysteria. Chinese Journal of the Practical Chinese with Modern Medicine 2004;4(19):2928-9.
39. Davis RH, Clench MH, Mathias JR. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study. Digestive Diseases and Sciences 1988;33(12):1505-11.
40. Farnbach P. A double-blind, randomised, placebo-controlled, flexible-dose of 50 mg/day to 400 mg/day, phase IIIb study of the efficacy and safety of quetiapine fumarate (Seroquel XR) as an add-on therapy in patients with chronic somatoform pain disorder. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12610000603011 (accessed 24 October 2014).
41. Fukuda I, Kamide H, Higuchi H, Fujiwara K, Nakamura Y, Hayashi M. Comparative evaluation of the effect on the psychosomatic symptoms between medazepam (s-804) and diazepam by means of double blind method [Comparative evaluation of the effect on the psychosomatic symptoms between medazepam (s-804) and diazepam by means of double blind method]. Modern Medicine 1971;26(8):1564-7.
42. Hasegawa N, Namiki M, Kawakami K, Sasaki D, Suzuki J, Ueno K, Mizushima N, Tanaka M, Kitanaka I, Ogawa C. The clinical efficacy of id-540, a psychotropic drug, for psychosomatic disease and neurosis: double-blind comparative study. Rinsyotokenkyu 1977;54(6):2075-85.
43. Holdevici I, Truia I, Girlasu O. The suggestive action of some 'placebo' medications in the balancing of patients with somatoform disorders. Revue Roumaine de Psychologie 1995;39(2):129-38.
44. Kozian R. Olanzapin in the therapy of a somatoform disorder [Olanzapin in der Therapie einer somatoformen Störung]. Fortbildung und Diskussion 2003;30:450-7.
45. Lee JH, Kim B, Kang EH, Yu BH. Anti-stress effect of Korean red ginseng (Panax ginseng C.A. Mayer) in healthy individuals with medically unexplained stress-related somatic symptoms: a randomized, double-blind, and placebo controlled clinical study. Proceedings of the 15th Pacific Rim College of Psychiatrists Scientific Meeting; 2012 Oct 25-27; Seoul, Korea. 2012.
46. Liu Y, Liu Z. Short-term deanxit in combination with sertraline treats somatic disease accompanied with depressive disorder. Study protocol (ChiCTR-TRC-11001732). www.chictr.org/en/proj/show.aspx?proj=2080 (accessed 24 October 2014).
47. Loldrup D, Langemarck M, Hansen H, Olesen J, Bech P. Clomipramine and mianserin in chronic idiopathic pain syndrome: a placebo controlled study. Psychopharmacology 1989;99(1):1-7.
48. Onghena P, De Cuyper H, Van Houdenhove B, Verstraeten D. Mianserin and chronic pain: a double-blind placebo-controlled process and outcome study. Acta Psychiatrica Scandinavica 1993;88(3):198-204.
49. Pach J, Waniek W. A comparison of the tranquilizing effect of fluspirilene and diazepam [Vergleichende Untersuchung zum Tranquilizereffekt von Fluspirilene und Diazepam]. Pharmakopsychiatrie, Neuro-Psychopharmakologie 1976;9(2):61-6.
50. Poinso Y, Gouvernet J, Sambuc R. A multicentre double-blind trial of sulpiride versus toloxatone in patients with reactive depressions and somatization receiving non-specialized care [Etude multicentrique en double insu sulpiride versus toloxatone dans les depressions reactionnelles avec somatisations en medecine generale]. Semaine des hopitaux 1988;64(17):1201-5.
51. Raich WA, Rickels K, Raab E. A double-blind evaluation of fenfluramine in anxious somatizing neurotic medical clinic patients. [1966]. Current Therapeutic Research, Clinical and Experimenta 1966;8(1):31-3.
52. Smith ME. A controlled comparative study of doxepin and chlordiazepoxide in psychoneurotic anxiety. Journal of Clinical Pharmacology & New Drugs 1971;11(2):152-6.
53. Smoulevich A, Tkhostov A, Ivanov S, Kolutskaya E. A study of the efficiency of therapy of cardioneurotic patients. Xth World Congress of Psychiatry, Madrid, Spain, 1996.
54. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder: a double-blind placebo-controlled study with mianserin. Scandinavian Journal of Gastroenterology 1996;31(4):318-25.
55. Tsutsui S, Katsunuma H, Hirai S, Katsura K, Suematsu H, Kikuchi N, et al.The clinical efficacy of brotizolam (we941), a hypnotic, by the double-blind method in the field of internal medicine (psychosomatic medicine), geriatric medicine. Journal of Clinical and Experimental Medicine, Medicine in Progress 1984;131(6):412-27.
56. Tsutsui S, Katsura T, Kono T, Oosita A, Saito T, Namba T. The clinical evaluation of efficacy and safety of brotizolam (we 941), a hypnotic, in the fields of internal medicine and psychosomatic medicine: A comparative study by the double-blind method. Medical Consultation & New Remedies 1985;22(1):41-56.
57. Tsutsui S, Katsura T, Kono T, Matsuzaki H, Yamamoto H, Yamaoka M, et al.The clinical evaluation of lormetazepam, a new hypnotic, in the field of internal medicine, psychosomatic medicine: a double-blind comparative study with haloxazolam. Japanese Journal of Clinical and Experimental medicine 1986;63(3):1627-64.
58. Tsutsui S, Katsura T, Kono T, Katsura K, Namba T, Kawano T. Multi-center double-blind clinical trial on 450191-s, a new hypnotic, in the field of psychosomatic medicine. Clinical Report 1987;1(8):3683-99.
59. Tsutsui S, Katsura T, Kono T, Ogawa C, Tanaka M. Dose-finding study of sch161 in the field of psychosomatic medicine: double-blind comparative study with placebo. Journal of Clinical Therapeutics and Medicine 1992;8(2):335-56.
60. Turkington D, Grant JB, Ferrier IN, Rao NS, Linsley KR, Young AH. A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. Journal of Clinical Psychiatry 2002;63(9):778-81.
61. Xu Y, Fu C. A comparative study of paroxetine versus acupuncture-therapy in treatment of somatization disorder. Journal of Practical Medical Techniques 2006;13(13):2302-3.
62. Zang DX. A self body double blind clinical study of L-tryptophan and placebo in treated neurosis. Chinese Journal of Neurology and Psychiatry 1991;24(2):77-80.
63. Zhao H, Chang ZZ, Cao ML, Zang DX. A self-body double-blind trial of L-tryptophan in neurosis and depression. Acta Academiae Medicinae Hubei 1989;10(3):256-9.
64. Zitman FG, Linssen ACG, Edelbroek PM, Stijnen T. Low-dose amitriptyline in chronic pain: the gain is modest. Pain 1990;42(1):35-42.
65. Agger J, Schroder A, Fink P, Gormsen L, Jensen TS. Pharmacological treatment of multi-organ bodily distress syndrome: a double-blind, placebo-controlled trial of the effects of imipramine (STreSS-3). Journal of Psychosomatic Research 2013;75(2):196.
66. Fink PK. Treatment of multi-organ bodily distress syndrome. A double-blinded placebo controlled trial of the effect of imipramine (STreSS-3) - Stress-3. Study protocol. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-004294-87-DK (accessed 24 October 2014).
67. Fink PK, Agger JL. Imipramine treatment for patients with multi-organ bodily distress syndrome (STreSS-3). Study protocol. clinicaltrials.gov/show/NCT01518634 (accessed 24 October 2014).
68. Fink PK, Agger JL. Imipramine treatment for patients with multi-organ bodily distress syndrome. Study protocol. www.controlled-trials.com/mrct/trial/2272077/ (accessed 24 October 2014).
69. Allen LA, Escobar JI, Lehrer PM, Gara MA, Woolfolk RL. Psychosocial treatments for multiple unexplained physical symptoms: a review of literature. Psychosomatic Medicine 2002;64(6):393-50.
70. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
71. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM III). 3rd Edition. Washington, DC: American Psychiatric Press, 1980.
72. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders (DSM IV). 4th Edition. Washington, DC: American Psychiatric Press, 1994.
73. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR). 4th edition, text revision. Washington, DC: American Psychiatric Press, 2000.
74. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM III).. Diagnostic and Statistical Manual of Mental Disorders. Fifth edition. DSM-5. Washington, DC: American Psychiatric Press, 2013.
75. Atkinson JH, Kremer EF, Garfin SR. Psychopharmacological agents in the treatment of pain. Journal of Bone and Joint Surgery - American Volume 1985;67A(2):337-42.
76. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Guideline for the treatment of patients with non-specific, functional and somatoform physical complaints [Leitlinie zum Umgang mit Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden]. AWMF 2012.
77. Barsky AJ, Wyshak GL. Hypochondriasis and somatosensory amplification. British Journal of Psychiatry 1990;157:404-9.
78. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Archives of General Psychiatry 2005;62:903-10.
79. Beck AT, Erbaugh J, Ward CH, Mock J, Mendelsohn M. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71.
80. Beck AT, Steer RA. Beck Anxiety Inventory Manual. San Antonio, TX: The Psychological Corporation, Harcourt Brace, 1990.
81. Bergin AE. The evaluation of therapeutic outcomes. Handbook of Psychotherapy and Behavior Change. 1. New York: Wiley, 1971:217-70.
82. Bonaz B, Baciu M, Papillon E, Bost R, Gueddah N, Le Bas JF, et al.Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. American Journal of Gastroenterology 2002;97:654-61.
83. Butterweck V. Mechanism of action of St John's wort in depression - what is known?. CNS Drugs 2003;17:539-62.
84. Chinese Society of Psychiatry. The Chinese Classification and Diagnostic Criteria of Mental Disorders Version 3 (CCMD-3). Jinan: Chinese Society of Psychiatry, 2001.
85. Clayton AH. Gender differences in clinical psychopharmacology. Journal of Clinical Psychiatry 2005;66:1191.
86. Creed F, Barsky AJ, Leiknes KA. Epidemiology: prevalence, causes and consequences. In: Creed F, Henningsen P, Fink P editor(s). Medically Unexplained Symptoms, Somatisation and Bodily Distress. New York: Cambridge University Press, 2011.
87. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. British Journal of Psychiatry 2004;184:470-6.
88. Decoutere L, van den Eede F, Moorkens G, Sabbe BG. Antipsychotic agents in the treatment of somatoform disorders: a review [Gebruik van antipsychotica bij somatoformestoornissen; een literatuuroverzicht]. Tijdschrift voor Psychiatrie 2011;53(3):163-73.
89. Derogatis LR. The SCL-90-R Manual. Scoring and Administration Procedures for the SCL-90-R. Baltimore, MA: John Hopkins University School of Medicine, 1983.
90. Derogatis LR. The Brief Symptom Inventory (BSI): Administration, Scoring, and Procedures Manual II. Baltimore, MD: Clinical Psychometric Research, 1992.
91. Di Franco M, Iannuccelli C, Atzeni F, Cazzola M, Salaffi F, Valesini G, et al.Pharmacological treatment of fibromyalgia. Clinical and Experimental Rheumatology 2010;28(6):S110-6.
92. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, et al.Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31.
93. Escobar JI, Burnam MA, Karno M, Forsythe A, Golding JM. Somatization in the community. Archives of General Psychiatry 1987;44:713-18.
94. Escobar JI. Pharmacological treatment of somatization/hypochondriasis. Psychopharmacology Bulletin 1996;32:589-96.
95. Fallon BA. Pharmacotherapy of somatoform disorders. Journal of Psychosomatic Research 2004;56(4):455-60.
96. Fink P, Schröder A. One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders. Journal of Psychosomatic Research 2010;68:415-26.
97. Fink PK. Treatment of multi-organ bodily distress syndrome. A double-blinded placebo controlled trial of the effect of imipramine (STreSS-3) - Stress-3. Study protocol. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-004294-87-DK (accessed 24 October 2014).
98. Fink PK, Agger JL. Imipramine treatment for patients with multi-organ bodily distress syndrome (Stress-3). Study protocol. clinicaltrials.gov/show/NCT01518634 (accessed 24 October 2014).
99. Fink PK, Agger JL. Imipramine treatment for patients with multi-organ bodily distress syndrome. Study protocol. www.controlled-trials.com/mrct/trial/2272077/ (accessed 24 October 2014).
100. Fishbain DA, Cutler RB, Rosomoff HL, Steele-Rosomoff RS. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosomatic Medicine 1998;60(4):503-9.
101. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-78.
102. Fournier JC, DeRubeis RR, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al.Antidepressant drug effects and depression severity: a patient-level meta-analysis. Journal of the American Medical Association 2010;303(1):47-53.
103. Fröhlich C, Jacobi F, Wittchen HU. DSM-IV pain disorder in the general population - an exploration of the structure and threshold of medically unexplained pain symptoms. European Archives of Psychiatry and Clinical Neuroscience 2006;256:187-96.
104. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58:579-88.
105. Gildenberg PL. Management of chronic pain. Applied Neurophysiology 1984;47(4-6):157-70.
106. Gorard DA, Libby GW, Farthing MJG. Influence of antidepressants on whole gut and orocecal transit times in health and irritable-bowel-syndrome. Alimentary Pharmacology & Therapeutics 1994;8:159-66.
107. Grabe HJ, Meyer C, Hapke U, Rumpf HJ, Freyberger HJ, Dilling H, et al.Specific somatoform disorder in the general population. Psychosomatics 2003;44:304-11.
108. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004;24(5):621-9.
109. Gu YP, Huang LYM. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. Neuroscience Letters 2002;324:177-80.
110. Gureje O. What can we learn from a cross-national study of somatic distress?. Journal of Psychosomatic Research 2004;56(4):409-12.
111. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health, 1976:218-22.
112. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
113. Hamilton M. The assessment of anxiety states by rating. British Journal of Psychiatry 1959;32:50-5.
114. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960;23:56-62.
115. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 2006;163(2):185-94.
116. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane.org.
117. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
118. Hoedeman R, Blankenstein NAH, van der Feltz-Cornelis CM, Krol B, Groothoff JJW. Consultation letters for medically unexplained physical symptoms in primary care. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD006524.pub2].
119. Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C, Martin AE. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD003017.pub3].
120. Häuser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. Journal of the American Medical Association 2009;301:198-209.
121. Ipser JC, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005332.pub2].
122. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. American Journal of Medicine 2000;108:65-72.
123. Jackson JL, O'Malley PG, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectrums 2006;11:212-22.
124. Jackson JL, Kroenke K. Managing somatization: medically unexplained should not mean medically ignored. Journal of General Internal Medicine 2006;21(7):797-9.
125. Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, et al.Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychological Medicine 2004;34:597-611.
126. Janca A, Hiller W. CD-10 Checklists - a tool for clinicians' use of the ICD-10 classification of mental and behavioral disorders. Comprehensive Psychiatry 1996;37:180-7.
127. Johansson F. Patients with Chronic Pain. A Clinical, Clinical-pharmacological and Biochemical Study [medical dissertation]. Umeå, Sweden: Umeå University, 1982.
128. Jones SL. Descending noradrenergic influences on pain. Progress in Brain Research 1991;88:381-94.
129. Katz J, Melzack R. Measurement of pain. Surgical Clinics of North America 1999;79:231-52.
130. Kellner R. Somatization and Hypochondriasis. New York: Praeger-Greenwood Publishers, 1986.
131. Kirmayer LJ, Looper KJ, Taillefer, S. Somatoform disorders. In: Turner SM, Hersen M editor(s). Adult Psychopathology and Diagnosis. 4th Edition. New York: John Wiley, 1997:420-75.
132. Kleinstäuber M, Witthöft M, Hiller W. Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis. Clinical Psychology Review 2011;31(1):146-60.
133. Kroenke K, Spitzer RL, deGruy RV, Hahn SR, Linzer M, Williams JB. Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Archives of General Psychiatry 1997;54:352-8.
134. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine 2002;64:258-66.
135. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosomatic Medicine 2007;69(9):881-8.
136. Kubera N, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. Journal of Clinical Psychopharmacology 2001;21:199-206.
137. Lambert MJ, Hatch DR, Kingston MD, Edwards BC. Zung, Beck, and Hamilton Rating Scales as measures of treatment outcome: a meta-analytic comparison. Journal of Consulting and Clinical Psychology 1986;54(1):54-9.
138. Lambert MJ, Hill CE. Assessing psychotherapy outcomes and process. In: Bergin AE, Garfield SL editor(s). Handbook of Psychotherapy and Behavior Change. 4th Edition. New York: Wiley, 1994:72-113.
139. Leiknes KA, Finset A, Moum T, Sandanger I. Course and predictors of medically unexplained pain symptoms in the general population. Journal of Psychosomatic Research 2007;62(2):119-28.
140. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70.
141. Linde K. St. John's wort - an overview. Forschende Komplementärmedizin 2009;16:146-55.
142. Lipman RS, Chase C, Rickles K, Covi L, Derogatis LR, Uhlenhuth EH. Factors of symptom distress. Doctor ratings of anxious neurotic outpatients. Archives of General Psychiatry 1969;21:328-31.
143. Loder EW, Biondi DM. Off-label prescribing of drugs in specialty headache practice. Headache 2004;44(7):636-41.
144. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. Journal of Psychiatry & Neuroscience 2001;26(1):30-6.
145. Maes M. Major depression and activation of the inflammatory response system. Cytokines, Stress, and Depression 1999;461:25-46.
146. Maes M. The immunoregulatory effects of antidepressants. Human Psychopharmacology - Clinical and Experimental 2001;16:95-103.
147. Magni G. The use of antidepressants in the treatment of chronic pain: a review of the current evidence. Drugs 1991;42(5):730-48.
148. Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Current Neuropharmacology 2009;7(4):331-6.
149. Martin A, Jacobi F. Features of hypochondriasis and illness worry in the general population in Germany. Psychosomatic Medicine 2006;68:770-7.
150. Mcquay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995;311(7012):1047-52.
151. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
152. Meyer C, Rumpf HJ, Hapke U, John U. Prevalence of DSM-IV psychiatric disorders including nicotine dependence in the general population: results from the Northern German TACOS study. Neurology Psychiatry and Brain Research 2001;9:75-80.
153. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Medical Research Methodology 2001;1:2.
154. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097.
155. Montoya P, Pauli P, Batra A, Wiedemann G. Altered processing of pain-related information in patients with fibromyalgia. European Journal of Pain 2005;9:293-303.
156. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2].
157. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2].
158. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2].
159. Mumford DB, Bavington JT, Bhatnagar KS, Hussain Y, Mirza S, Naraghi MM. The Bradford Somatic Inventory - a multiethnic inventory of somatic symptoms reported by anxious and depressed patients in Britain and the Indo-Pakistan subcontinent. British Journal of Psychiatry 1991;158:379-86.
160. Naliboff BD, Munakata J, Fullerton S, Gracely RH, Kodner A, Harraf F, et al.Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 1997;41:505-12.
161. Nimnuan C, Hotopf M, Wessely S. Medically unexplained symptoms: an epidemiological study in seven specialities. Journal of Psychosomatic Research 2001;51:361-7.
162. Nix WA. What is certain in pain therapy? The analgesic potency of neuroleptics in the treatment of chronic pain. A meta-analysis [Was ist gesichert in der Schmerztherapie? Haben Neuroleptika eine analgetische Potenz? Eine Metaanalyse]. Schmerz 1998;12:30-8.
163. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained medical symptoms and syndromes. Journal of Family Practice 1999;48(12):980-90.
164. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. Journal of General Internal Medicine 2000;15:659-66.
165. Pae CU, Marks DM, Patkar AA, Masand PS, Luyten P, Serretti A. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opinion on Pharmacotherapy 2009;10:1561-70.
166. Petzke F, Harris RE, Williams DA, Clauw DJ, Gracely RH. Differences in unpleasantness induced by experimental pressure pain between patients with fibromyalgia and healthy controls. European Journal of Pain 2005;9:325-35.
167. Pilowsky I. Dimensions of hypochondriasis. British Journal of Psychiatry 1967;113:89-93.
168. Price J. Review: antidepressants are effective for clinical unexplained symptoms and syndromes. Evidence Based Mental Health 2000;3:84.
169. Prior KN, Bond MJ. Somatic symptom disorders and illness behaviour: current perspectives. International Review of Psychiatry 2013;25(1):5-18.
170. Raine R, Haines A, Sensky T, Hutchings A, Larkin K, Black N. Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care?. BMJ 2002;325(7372):1082.
171. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
172. Richardson BP. Serotonin and nociception. Annals of the New York Academy of Sciences 1990;600:511-20.
173. Rickels K, Noyes RJ, Robinson DS, Schweizer E, Uhlenhut EH. Evaluating drug treatments of generalized anxiety disorder and adjustment disorders with anxious mood. In: Prien RF, Robinson DS editor(s). Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York: Raven Press, 1994:373-410.
174. Rief W, Hiller W, Margraf J. Cognitive aspects of hypochondriasis and the somatization syndrome. Journal of Abnormal Psychology 1998;107:587-95.
175. Rief W, Hiller W. Toward empirically based criteria for the classification of somatoform disorders. Journal of Psychosomatic Research 1999;46:507-18.
176. Rief W, Ihle D, Pilger F. A new approach to assess illness behaviour. Journal of Psychosomatic Research 2003;54:405-14.
177. Rief W, Barsk AJ. Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology 2005;30:996-1002.
178. Rief W, Broadbent E. Explaining medically unexplained physical symptoms - models and mechanisms. Clinical Psychology Review 2007;27:821-41.
179. Rief W, Hiller W. SOMS Screening for Somatoform Disorders [SOMS Das Screening für Somatoforme Störungen. Manual zum Fragebogen]. 4th Edition. Bern, Switzerland: Huber, 2008.
180. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. Journal of Affective Disorders 2009;118:1-8.
181. Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. New York: The Free Press, 1991.
182. Ruddy R, House A. Psychosocial interventions for conversion disorder. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005331.pub2].
183. Ryder AG, Yang J, Zhu XZ, Yao SQ, Yi JY, Heine SJ, et al.The cultural shaping of depression: somatic symptoms in China, psychological symptoms in North America?. Journal of Abnormal Psychology 2008;117(2):300-13.
184. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2].
185. Satterthwaite JR, Tollison CD, Kriegel ML. The use of tricyclic antidepressants for the treatment of intractable pain. Comprehensive Therapy 1990;16(4):10-5.
186. Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacology Biochemistry and Behavior 1999;64:75-80.
187. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
188. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD004844.pub2].
189. Sharma MP, Manjula M. Behavioural and psychological management of somatic symptom disorders: an overview. International Review of Psychiatry 2013;25(1):116-24.
190. Sharpe M, Mayou R, Bass C. Concepts, theories and terminology. In: Mayou R, Bass C, Sharpe M editor(s). Treatment of Functional Somatic Symptoms. Oxford: Oxford University Press, 1995:3-16.
191. Sheehan DV. The Anxiety Disease. New York: Scribner, 1983.
192. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al.The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998;59:22-33.
193. Silberstein SD, Peres MFP, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002;42:515-8.
194. Somashekar B, Jainer A, Wuntakal B. Psychopharmacotherapy of somatic symptoms disorders. Review. International Review of Psychiatry 2013;25(1):107-15.
195. Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of an Hypericum preparation in 105 patients with depressions. Nervenheilkunde 1993;12:274-7.
196. Stahl SM. The psychopharmacology of painful physical symptoms in depression. Journal of Clinical Psychiatry 2002;63:382-3.
197. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting bias. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
198. Stone KJ, Viera AJ, Parman CL. Off-label applications for SSRIs. American Family Physician 2003;68(3):498-504.
199. Suls J, Howren MB. Understanding the physical-symptom experience: the distinctive contributions of anxiety and depression. Current Directions in Psychological Science 2012;21(2):129-34.
200. Sumathipala A. What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosomatic Medicine 2007;69(9):889-900.
201. Thomson AB, Page LA. Psychotherapies for hypochondriasis. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006520.pub2].
202. Urban MO, Ren K, Park KT, Campbell B, Anker N, Stearns B, et al.Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. Journal of Pharmacology and Experimental Therapeutics 2005;31:1209-16.
203. Ursin H. Sensitization, somatization, and subjective health complaints. International Journal of Behavioral Medicine 1997;4:105-16.
204. Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
205. Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs 2008;68:2611-32.
206. Verhaak PF, Meijer SA, Visser AP, Wolters G. Persistent presentation of medically unexplained symptoms in general practice. Family Practice 2006;23:414-20.
207. Volz HP, Murck H, Kasper S, Moller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Erratum [Johanniskrautextrakt (LI 160) bei somatoformen Stoerungen: Ergebnisse einer plazebokontrollierten Studie. Erratum]. Psychopharmacology 2003;167(3):333.
208. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36) .1. Conceptual-framework and item selection. Medical Care 1992;30:473-83.
209. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many?. Lancet 1999;354:936-9.
210. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. Gastroenterology 2002;122:1140-56.
211. World Health Organization. International Classification of Diseases. 9th revision (ICD-9). Geneva, Switzerland: World Health Organization, 1975.
212. World Health Organization. International Statistical Classification of Diseases. 10th Revision (ICD-10). Geneva, Switzerland: World Health Organization, 1992.
213. Williams JBW, Spitzer RL. Idiopathic pain disorder: a critique of pain-prone disorder and a proposal for a revision of the DSM-III category psychogenic pain disorder. Journal of Nervous and Mental Disease 1982;170:415-9.
214. Wittchen HU, Essau CA, Vonzerssen D, Krieg JC, Zaudig M. Lifetime and 6-month prevalence of mental disorders in the Munich follow-up-study. European Archives of Psychiatry and Clinical Neuroscience 1992;241:247-58.
215. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. European Neuropsychopharmacology 2005;15:357-76.
216. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al.The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011;21:655-79.
217. Witthöft M, Hiller W. Psychological approaches to origins and treatments of somatoform disorders. Annual Review of Clinical Psychology 2010;6:257-83.
218. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 2000;321:536-9.
219. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Research 1996;711(1-2):163-74.
220. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Seminars in Arthritis and Rheumatism 2007;36:339-56.